by In2Pharma | Jul 7, 2020 | News
The Netherlands On the basis of scientific conditions, the Medicines Evaluation Board (MEB) will draw up a list of medicines for which switching is undesirable. It will do this in the interests of patient safety. Medicines with the same active ingredient, dosage and...
by In2Pharma | Jun 11, 2020 | News
The Netherlands The Medicines Evaluation Board (MEB) recently revised 2 policy documents relating to the requirements for product information: “labelling of pharmaceutical products” and “Nomenclature of pharmaceutical products”. The revision only applies to medicinal...
by In2Pharma | Nov 5, 2019 | News
The Netherlands The Medicines Evaluation Board (MEB) invites interested parties and stakeholders to comment on 2 amended policy documents on the labeling of medicines for humans (MEB 6) and the naming of pharmaceutical products (MEB 13). The most important changes are...
by In2Pharma | May 9, 2019 | News
The Netherlands The Medicines Evaluation Board (MEB) will no longer publish full product information about the active substance of generic medicines on its website if there is still a patent on one of the indications. A generic drug may not be sold for indications...
by In2Pharma | Oct 15, 2018 | News
The Netherlands An ‘Advisory Group on the Status Determination of Medicinal Products has been established in the Netherlands. This Advisory Group is composed of expert representatives from IGJ, NVWA, MEB and CCMO. The ‘Advisory Group’ advises on...